Last reviewed · How we verify
recombinant human Angiostatin protein
recombinant human Angiostatin protein is a Small molecule drug developed by CASI Pharmaceuticals, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | recombinant human Angiostatin protein |
|---|---|
| Sponsor | CASI Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant human Angiostatin protein CI brief — competitive landscape report
- recombinant human Angiostatin protein updates RSS · CI watch RSS
- CASI Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about recombinant human Angiostatin protein
What is recombinant human Angiostatin protein?
recombinant human Angiostatin protein is a Small molecule drug developed by CASI Pharmaceuticals, Inc..
Who makes recombinant human Angiostatin protein?
recombinant human Angiostatin protein is developed by CASI Pharmaceuticals, Inc. (see full CASI Pharmaceuticals, Inc. pipeline at /company/casi-pharmaceuticals-inc).
What development phase is recombinant human Angiostatin protein in?
recombinant human Angiostatin protein is in Phase 2.